B Group Inc. Purchases Shares of 90,000 Structure Therapeutics Inc. Sponsored ADR $GPCR

B Group Inc. purchased a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 90,000 shares of the company’s stock, valued at approximately $6,260,000. Structure Therapeutics accounts for approximately 4.6% of B Group Inc.’s portfolio, making the stock its 8th biggest position. B Group Inc. owned approximately 0.15% of Structure Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. CWM LLC increased its position in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares during the period. HighTower Advisors LLC increased its position in Structure Therapeutics by 3.6% in the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after acquiring an additional 320 shares during the period. State of Wyoming increased its position in Structure Therapeutics by 29.7% in the 4th quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after acquiring an additional 403 shares during the period. PNC Financial Services Group Inc. increased its position in Structure Therapeutics by 9.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock valued at $135,000 after acquiring an additional 413 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in Structure Therapeutics by 4.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after acquiring an additional 444 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on GPCR. Citizens Jmp decreased their price target on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. BMO Capital Markets set a $145.00 price objective on shares of Structure Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Wall Street Zen cut shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright decreased their price objective on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $106.75.

Structure Therapeutics Stock Down 0.4%

GPCR opened at $42.91 on Wednesday. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $15.80 and a twelve month high of $94.90. The company has a fifty day moving average of $43.22 and a 200-day moving average of $57.45. The stock has a market cap of $3.05 billion, a PE ratio of -49.32 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. Sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.